Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease : a Systematic Review and Meta-analysis
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. Endoscopic sleeve gastroplasty (ESG) has proven to be feasible, safe, and effective in the management of obesity. We performed the first systematic review and meta-analysis evaluating NAFLD and other metabolic parameters 12 months post-ESG. Four observational studies with a total of 175 patients were included. The results showed a significant (p < 0.05) reduction of 4.85 in hepatic steatosis index (95% CI - 6.02, - 3.67), 0.5 in NAFLD fibrosis score (95% CI - 0.80, - 0.19), 6.32 U/l in ALT (95% CI - 9.52, - 3.11), 17.28% in TWL (95% CI - 18.24, - 16.31), 6.31 kg/m2 in BMI (95% CI - 8.11, - 4.52), 47.97% in EWL (95% CI - 49.10, - 46.84), and 0.51% in HbA1c (95% CI - 0.90, - 0.12). ESG improves liver parameters, provides weight loss, and reduces HbA1c levels in patients suffering from NAFLD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Obesity surgery - 33(2023), 9 vom: 03. Sept., Seite 2917-2926 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nunes, Beanie Conceição Medeiros [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bariatric |
|---|
| Anmerkungen: |
Date Completed 18.08.2023 Date Revised 19.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11695-023-06747-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360372287 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360372287 | ||
| 003 | DE-627 | ||
| 005 | 20231226082857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11695-023-06747-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360372287 | ||
| 035 | |a (NLM)37537506 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nunes, Beanie Conceição Medeiros |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease |b a Systematic Review and Meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2023 | ||
| 500 | |a Date Revised 19.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. Endoscopic sleeve gastroplasty (ESG) has proven to be feasible, safe, and effective in the management of obesity. We performed the first systematic review and meta-analysis evaluating NAFLD and other metabolic parameters 12 months post-ESG. Four observational studies with a total of 175 patients were included. The results showed a significant (p < 0.05) reduction of 4.85 in hepatic steatosis index (95% CI - 6.02, - 3.67), 0.5 in NAFLD fibrosis score (95% CI - 0.80, - 0.19), 6.32 U/l in ALT (95% CI - 9.52, - 3.11), 17.28% in TWL (95% CI - 18.24, - 16.31), 6.31 kg/m2 in BMI (95% CI - 8.11, - 4.52), 47.97% in EWL (95% CI - 49.10, - 46.84), and 0.51% in HbA1c (95% CI - 0.90, - 0.12). ESG improves liver parameters, provides weight loss, and reduces HbA1c levels in patients suffering from NAFLD | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bariatric | |
| 650 | 4 | |a ESG | |
| 650 | 4 | |a Endoscopic sleeve gastroplasty | |
| 650 | 4 | |a Fatty liver disease | |
| 650 | 4 | |a NAFLD | |
| 650 | 4 | |a Obesity | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 700 | 1 | |a de Moura, Diogo Turiani Hourneaux |e verfasserin |4 aut | |
| 700 | 1 | |a Kum, Angelo So Taa |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Guilherme Henrique Peixoto |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Bruno Salomão |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, Igor Braga |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Igor Logetto Caetité |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Claudia Pinto Marques |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmood, Sultan |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardo, Wanderley Marques |e verfasserin |4 aut | |
| 700 | 1 | |a de Moura, Eduardo Guimarães Hourneaux |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obesity surgery |d 1991 |g 33(2023), 9 vom: 03. Sept., Seite 2917-2926 |w (DE-627)NLM090631897 |x 1708-0428 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:9 |g day:03 |g month:09 |g pages:2917-2926 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11695-023-06747-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 9 |b 03 |c 09 |h 2917-2926 | ||